BCHE and Alzheimer disease: Most enrolled participants would be characterized as early AD (Stage 3) [38] with baseline MMSE score 20–28, and the majority were on background therapy of cholinesterase inhibitors (ChEIs) and/or memantine to treat AD (Table 1).